# US 2010/0247578 A1 · Carrier system for biological agents containing organosilicon compounds and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2010/0247578 A1
- Document ID: US20100247578A1
- Status: Published application
- Kind: A1
- Application number: 12/744,119
- Filed: 2009-08-17
- Published: 2010-09-30
- Earliest claimed: 2008-08-15
- Inventors: Zoser B. Salama
- Web page: https://patentgrep.com/patent/US20100247578A1

## CPC

- A61K 9/1272: comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers (lipids as modifying agents {A61K47/543})
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/19: lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)}
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/35: Allergens
- A61K 47/24: containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to a novel organosilicon carrier system for biological agents that is produced via a simple, stable and reproducible preparation process that is capable of maintaining tertiary protein structure and biological activity of the proteins and/or other biological agents in the mixture, whereby the carrier system is obtainable by mixing one or more organosilicon compounds, selected from the group comprising organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with one or more biological agents, selected from the group comprising antigens, preantigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics, in solution at a pH value between 7 and 8, preferably 7.4, followed by homogenisation or sonication of the mixture, followed by sterile filtration of the mixture, followed by lyophilisation.

## Claims

### Claim 1

Carrier system for biological agents obtainable by
a) mixing one or more organosilicon compounds, selected from the group comprising:
organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with
one or more biological agents, selected from the group comprising:
Antigens, pre-antigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics,
in solution at a pH value between 7 and 8, preferably 7.4, followed by
b) homogenisation or sonication of the mixture, followed by
c) sterile filtration of the mixture, followed by
d) lyophilisation.

### Claim 2 (depends on 1)

Carrier system for biological agents according to claim 1, comprising organosilicon, sugar organosilicon, or aminosugar organosilicon compounds of the general formula 1:
R1 and R2, which can be the same or different, each represent an acyloxy residue of the formula R—COO— or a peptide residue of the formula
wherein R represents an unbranched or branched alkyl, alkenyl or alkinyl residue with 5 to 29 C atoms which can be substituted by one to three halogen atoms, alkoxy residues with 1 to 18 C atoms or amino groups, the residues R5, which can be the same or different, represent the residue remaining after the removal of the group
from an amino acid occurring in nature, the residues X, which may be the same or different, represent a hydrogen atom or an amino-protective group usually occurring in peptide chemistry and n represents an integer from 1 to 12 and R3 and R4 which can be the same or different, each represent an aryl group, such as a phenyl group, or the residue remaining after the removal of a hydrogen atom from a monosaccharide, disaccharide, amino sugar or a hydroxyl carbon acid, or alkoxy residues with 1-5 C atoms, or acyl residues of an amino acid occurring in nature with a free or protected amino group, or a dipeptide, tripeptide or tetrapeptide residue of an amino acid occurring in nature with free or protected amino groups, or they have the meaning R1 and R2, with R representing an unbranched or branched alkyl, akenyl or alkinyl residue.

### Claim 3 (depends on 1, 2)

Carrier system according to claim 1 or 2 comprising organosilicon, sugar organosilicon and/or amino sugar organosilicon compounds covalently attached to one or more of the antigens, antibodies and/or other biological agents.

### Claim 4 (depends on 1, 2)

Method for producing the carrier system according claim 1 or 2, comprising
a) mixing one or more organosilicon compounds, selected from the group comprising:
organosilicon, sugar organosilicon, amino sugar organosilicon compounds, their derivatives, salts and/or the vesicles formed from them, with
one or more biological agents, selected from the group comprising: antigens, pre-antigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances and/or cosmetics,
in solution at a pH value between 7 and 8, preferably 7.4, followed by
b) homogenisation or sonication of the mixture, followed by
c) sterile filtration of the mixture, followed by
d) lyophilisation.

### Claim 5 (depends on 4)

Method of claim 4, wherein the method is carried out between 4° C. and 37° C., particularly at 4° C.

### Claim 6 (depends on 4)

The carrier system obtainable by the production method according to claim 4.

### Claim 7 (depends on 1, 2)

The carrier system according to claim 1 or 2, wherein said carrier system is a targeting system for biological agents.

### Claim 8 (depends on 1, 2)

The carrier system according to claim 1 or 2 wherein said carrier system is part of a cancer diagnostics.

### Claim 9 (depends on 1, 2)

Method for producing a pharmaceutical composition for the treatment of cancer comprising providing a carrier system according to claim 1 or 2 and producing said pharmaceutical composition.

### Claim 10 (depends on 1, 2)

The carrier system according to claim 1 or 2 wherein said carrier system is a constituent in a vaccine for therapeutic or prophylactic vaccination in humans and higher animals.

### Claim 11 (depends on 1, 2)

The carrier system according to claim 1 or 2 wherein said carrier system is a constituent in an immunotherapeutic for the desensitization of allergies in humans and higher animals.

### Claim 12 (depends on 1, 2)

The carrier system according to claim 1 or 2 wherein the carrier system contains one or more house dust mite allergens as immunotherapeutic and/or vaccine for the prevention and/or treatment of allergic disorders caused by house dust mite allergens, including anaphylaxis, seasonal hay fever, atopic dermatitis and allergic asthma.

### Claim 13 (depends on 1, 2)

Method for producing a pharmaceutical composition for the treatment of infectious, acute, chronic and life threatening diseases comprising providing a carrier system according to claim 1 or 2 and producing said pharmaceutical composition for the treatment of infectious, acute, chronic and life threatening diseases.

### Claim 14 (depends on 1, 2)

Method for preparing cosmetics comprising providing a carrier system according to claim 1 or 2 and preparing said cosmetics.

### Claim 15 (depends on 1, 2)

A kit for preparing the carrier system according to claim 1 or 2, wherein the silicon organic compound, sugar organosilicon and/or amino sugar organosilicon compounds, its derivatives, vesicles prepared from them are stored in a separate container from the biological agents, antigens, pre-antigens, antigen conjugates, antibodies, pre-antibodies, antibody conjugates, allergens, allergen extracts, nucleic acids, plasmids, proteins, peptides, pharmaceutical agents, immunologically active substances, cosmetics, additives, adjuvants, and solvents for reconstitution such as sterile water, detergent buffer or oil, allowing the administration of different concentrations and combinations of various agents, and wherein information about using parts of the kit is provided.
